• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HCC 肝移植等候名单在强制 6 个月等候时间前后的退出率。

HCC Liver Transplantation Wait List Dropout Rates Before and After the Mandated 6-Month Wait Time.

机构信息

Department of Transplant Surgery, Tampa General Medical Group, Tampa, FL, USA.

Morsani College of Medicine, University of South Florida, Tampa, FL, USA.

出版信息

Am Surg. 2020 Nov;86(11):1592-1595. doi: 10.1177/0003134820942165. Epub 2020 Aug 19.

DOI:10.1177/0003134820942165
PMID:32812771
Abstract

BACKGROUND

Studies have shown significant improvement in hepatocellular carcinoma (HCC) recurrence rates after liver transplantation since the united network of organ sharing (UNOS) implementation of a 6-month wait period prior to accrued exception model for end-stage liver disease (MELD) points enacted on October 8, 2015. However, few have examined the impact on HCC dropout rates for patients awaiting liver transplant. Our objective is to evaluate the outcomes of HCC dropout rates before and after the mandatory 6-month wait policy enacted.

METHODS

We conducted a retrospective cohort study on adult patients added to the liver transplant wait list between January 1, 2012, and March 8, 2019 (n = 767). Information was obtained through electronic medical records and organ procurement and transplant network (OPTN) publicly available national data reports.

RESULTS

In response to the 2015 UNOS-mandated 6-month wait time, dropout rates in the HCC patient population at our center increased from 12% pre-mandate to 20.8% post-mandate This increase was similarly reflected in the national dropout rate, which also increased from 26.3% pre-mandate to 29.0% post-mandate.

DISCUSSION

From these changes, it is evident that the UNOS mandate achieved its goal of increasing equity of liver organ allocation, but HCC patients are nonetheless dropping off of the wait list at an increased rate and are therefore disadvantaged.

摘要

背景

自 2015 年 10 月 8 日美国器官共享联合网络(UNOS)实施累积终末期肝病模型(MELD)评分前 6 个月等待期例外政策以来,研究表明肝癌(HCC)患者在肝移植后复发率显著降低。然而,很少有研究检查这对等待肝移植的 HCC 患者的脱落率的影响。我们的目的是评估在强制性 6 个月等待政策实施前后 HCC 脱落率的结果。

方法

我们对 2012 年 1 月 1 日至 2019 年 3 月 8 日期间加入肝移植等待名单的成年患者进行了回顾性队列研究(n=767)。信息通过电子病历和器官采购与移植网络(OPTN)的公开全国数据报告获得。

结果

为了响应 2015 年 UNOS 的 6 个月等待时间要求,我们中心 HCC 患者人群的脱落率从命令前的 12%增加到命令后的 20.8%。全国范围内的脱落率也同样增加,从命令前的 26.3%增加到命令后的 29.0%。

讨论

从这些变化可以明显看出,UNOS 的命令实现了增加肝脏器官分配公平性的目标,但 HCC 患者的等待名单脱落率仍在增加,因此处于不利地位。

相似文献

1
HCC Liver Transplantation Wait List Dropout Rates Before and After the Mandated 6-Month Wait Time.HCC 肝移植等候名单在强制 6 个月等候时间前后的退出率。
Am Surg. 2020 Nov;86(11):1592-1595. doi: 10.1177/0003134820942165. Epub 2020 Aug 19.
2
A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.一种用于肝细胞癌的新的候补者退出评分 - 确定一个可预测移植后生存状况更差的阈值。
J Hepatol. 2021 Apr;74(4):829-837. doi: 10.1016/j.jhep.2020.10.033. Epub 2020 Nov 11.
3
Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation.肝癌导致肝移植候补者不断退出,且地域差异不断扩大:对器官分配的影响。
Liver Transpl. 2018 Oct;24(10):1346-1356. doi: 10.1002/lt.25317.
4
Projected outcomes of 6-month delay in exception points versus an equivalent Model for End-Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates.对于肝细胞癌肝移植候选者,例外点延迟6个月与终末期肝病模型评分相当的预期结果。
Liver Transpl. 2016 Oct;22(10):1343-55. doi: 10.1002/lt.24503.
5
Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.强制性 6 个月等待期对肝癌患者等待名单和移植结果的影响。
Hepatology. 2020 Dec;72(6):2051-2062. doi: 10.1002/hep.31223. Epub 2020 Oct 22.
6
MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.MELDEQ:一种用于肝细胞癌患者的终末期肝病评分替代模型。
Liver Transpl. 2015 May;21(5):612-22. doi: 10.1002/lt.24098. Epub 2015 Apr 15.
7
Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation.长等待时间地区肝癌肝移植候补名单中低辍学风险的预测因素:对器官分配的影响。
Am J Transplant. 2019 Aug;19(8):2210-2218. doi: 10.1111/ajt.15353. Epub 2019 Apr 5.
8
Racial Disparities in Candidates for Hepatocellular Carcinoma Liver Transplant After 6-Month Wait Policy Change.肝癌患者在等待 6 个月政策改变后接受肝移植的种族差异。
JAMA Netw Open. 2023 Nov 1;6(11):e2341096. doi: 10.1001/jamanetworkopen.2023.41096.
9
A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.在终末期肝病模型系统内针对等待肝移植的肝细胞癌患者的一项新的优先政策。
Liver Transpl. 2007 Jun;13(6):857-66. doi: 10.1002/lt.21155.
10
Liver transplantation for hepatocellular carcinoma: the MELD impact.肝细胞癌的肝移植:终末期肝病模型(MELD)的影响
Liver Transpl. 2004 Jan;10(1):36-41. doi: 10.1002/lt.20012.

引用本文的文献

1
Hepatocellular Carcinoma: The Evolving Role of Systemic Therapies as a Bridging Treatment to Liver Transplantation.肝细胞癌:全身治疗作为肝移植桥接治疗的不断演变的作用
Cancers (Basel). 2024 May 30;16(11):2081. doi: 10.3390/cancers16112081.
2
Approach to immunotherapy for HCC in the liver transplant population.肝移植人群中肝癌的免疫治疗方法。
Clin Liver Dis (Hoboken). 2024 May 3;23(1):e0158. doi: 10.1097/CLD.0000000000000158. eCollection 2024 Jan-Jun.
3
Racial Disparities in Candidates for Hepatocellular Carcinoma Liver Transplant After 6-Month Wait Policy Change.
肝癌患者在等待 6 个月政策改变后接受肝移植的种族差异。
JAMA Netw Open. 2023 Nov 1;6(11):e2341096. doi: 10.1001/jamanetworkopen.2023.41096.
4
Outcomes and Patient Selection in Laparoscopic vs. Open Liver Resection for HCC and Colorectal Cancer Liver Metastasis.腹腔镜与开腹肝切除术治疗肝癌及结直肠癌肝转移的疗效及患者选择
Cancers (Basel). 2023 Feb 12;15(4):1179. doi: 10.3390/cancers15041179.
5
Race/Ethnicity Is Not Independently Associated with Risk of Adverse Waitlist Removal among Patients with HCC Exception Points.种族/族裔与肝癌例外点患者等待名单移除不良风险无独立关联。
J Clin Med. 2021 Dec 13;10(24):5826. doi: 10.3390/jcm10245826.